OM:HNSABiotechs
Hansa Biopharma (OM:HNSA) Stock Faces Deeper Q2 Loss Challenging Growth Optimism
Hansa Biopharma (OM:HNSA) has released its Q2 2026 results, reporting revenue of 48.1 million SEK, a basic EPS loss of 2.56 SEK, and net income excluding extra items showing a loss of 260.5 million SEK. These figures provide a snapshot of how the business is balancing growth and profitability. Over recent quarters, the company has reported revenue in a range between 30.8 million SEK and 75.99 million SEK, while quarterly basic EPS losses have ranged from 0.57 SEK to 2.56 SEK. This highlights...